The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions
Open accessAbstract
Since the approval of anti-CTLA4 therapy (ipilimumab) for late-stage melanoma in 2011, the development of anticancer immunotherapy agents has thrived. The success of many immune-checkpoint inhibitors has drastically changed the landscape of cancer treatment. For some types of cancer, monotherapy for targeting immune checkpoint pathways has proven more effective than traditional therapies, and combining immunotherapy with current treatment strategies may yield even better outcomes. Numerous preclinical studies have suggested that combining immunotherapy with radiotherapy could be a promising strategy for synergistic enhancement of treatment efficacy. Radiation delivered to the tumor site affects both tumor cells and surrounding stromal cells. Radiation-induced cancer cell damage exposes tumor-specific antigens that make them visible to immune surveillance and promotes the priming and activation of cytotoxic T cells. Radiation-induced modulation of the tumor microenvironment may also facilitate the recruitment and infiltration of immune cells. This unique relationship is the rationale for combining radiation with immune checkpoint blockade. Enhanced tumor recognition and immune cell targeting with checkpoint blockade may unleash the immune system to eliminate the cancer cells. However, challenges remain to be addressed to maximize the efficacy of this promising combination. Here we summarize the mechanisms of radiation and immune system interaction, and we discuss current challenges in radiation and immune checkpoint blockade therapy and possible future approaches to boost this combination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Sun, L., Wu, J., Du, F., Chen, X., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1232458 · Cited by 4,996
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 1×
“Recent studies have suggested that the response to immunotherapy could be predicted by the gut microbiome in mouse models (Vétizou et al., 2015) and melanoma patients (Gopalakrishnan et al., 2017).”
BackgroundNeoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 1×
“Recent studies have suggested that the response to immunotherapy could be predicted by the gut microbiome in mouse models (Vétizou et al., 2015) and melanoma patients (Gopalakrishnan et al., 2017).”
BackgroundCalreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
Ishikawa, H., Ma, Z., & Barber, G. N. (2009) · Nature · doi:10.1038/nature08476 · Cited by 2,759 · cited 2×
“When the presence of cytoplasmic DNA is detected, the product of cyclic GMP-AMP synthase (cGAS), cyclic GMPAMP (cGAMP), activates STING to upregulate transcription of a type I interferon gene through a STING-TBK-IRF3-NFκB signaling pathway (Ishikawa et al., 2009; Tanaka and Chen, 2012; Li et al., 2013; Sun et al., 201…”
BackgroundRadiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182
The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence
Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144 · cited 1×
“Several cytokines can be induced by radiation (Barker et al., 2015), one of the most critical of which is transforming growth factor β (TGF-β).”
BackgroundIrradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y.-X. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,105
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Vanpouille-Box, C., Alard, A., Aryankalayil, M. J., Sarfraz, Y., Diamond, J. M., Schneider, R. J., Inghirami, G., Coleman, C. N., Formenti, S. C., & Demaria, S. (2017) · Nature Communications · doi:10.1038/ncomms15618 · Cited by 1,834
Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737
Alsaab, H. O., Sau, S., Alzhrani, R., Tatiparti, K., Bhise, K., Kashaw, S. K., & Iyer, A. K. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00561 · Cited by 1,707
Dewan, M. Z., Galloway, A. E., Kawashima, N., Dewyngaert, J. K., Babb, J. S., Formenti, S. C., & Demaria, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0265 · Cited by 1,678
Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
Demaria, S., Ng, B., Devitt, M. L., Babb, J. S., Kawashima, N., Liebes, L., & Formenti, S. C. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.012 · Cited by 1,388
Lee, Y., Auh, S. L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., Beckett, M., Sharma, R., Chin, R., Tu, T., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206870 · Cited by 1,324
Self-citationSTING Specifies IRF3 Phosphorylation by TBK1 in the Cytosolic DNA Signaling Pathway
Tanaka, Y., & Chen, Z. J. (2012) · Science Signaling · doi:10.1126/scisignal.2002521 · Cited by 1,317
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Dovedi, S. J., Adlard, A. L., Lipowska-Bhalla, G., McKenna, C., Jones, S., Cheadle, E. J., Stratford, I. J., Poon, E., Morrow, M., Stewart, R., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1258 · Cited by 1,313
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302 · cited 1×
“A recent study in which mass cytometry was used to profile immune-cell infiltrates after treatment with either of two checkpoint inhibitors (anti-CTLA4 and anti-PD1) showed that the antitumor effects of each were driven by distinct mechanisms of action (Wei et al., 2017).”
BackgroundIdentification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., et al. (2017) · Nature · doi:10.1038/nature24462 · Cited by 1,191
Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,174
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142
Pivotal Roles of cGAS-cGAMP Signaling in Antiviral Defense and Immune Adjuvant Effects
Li, X.-D., Wu, J., Gao, D., Wang, H., Sun, L., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1244040 · Cited by 1,113
Shaverdian, N., Lisberg, A. E., Bornazyan, K., Veruttipong, D., Goldman, J. W., Formenti, S. C., Garon, E. B., & Lee, P. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30380-7 · Cited by 1,091
Radiotherapy and immunotherapy: a beneficial liaison?
Weichselbaum, R. R., Liang, H., Deng, L., & Fu, Y.-X. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.211 · Cited by 1,070
TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression
Yang, L., Pang, Y., & Moses, H. L. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.04.002 · Cited by 1,023
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Nishino, M., Ramaiya, N. H., Hatabu, H., & Hodi, F. S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.88 · Cited by 1,023
PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression
Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.-K., Hsu, J.-M., Hsu, J. L., Yu, W.-H., Du, Y., Lee, H.-H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3215 · Cited by 981
Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966
Watson, R. O., Manzanillo, P. S., & Cox, J. S. (2012) · Cell · doi:10.1016/j.cell.2012.06.040 · Cited by 755
PDL1 Regulation by p53 via miR-34
Cortez, M. A., Ivan, C., Valdecanas, D., Wang, X., Peltier, H. J., Ye, Y., Araujo, L., Carbone, D. P., Shilo, K., Giri, D. K., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv303 · Cited by 683
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
Łuksza, M., Riaz, N., Makarov, V., Balachandran, V. P., Hellmann, M. D., Solovyov, A., Rizvi, N. A., Merghoub, T., Levine, A. J., Chan, T. A., et al. (2017) · Nature · doi:10.1038/nature24473 · Cited by 646
Kumar, V., Chaudhary, N., Garg, M., Floudas, C. S., Soni, P., & Chandra, A. B. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00049 · Cited by 627
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
Germano, G., Lamba, S., Rospo, G., Barault, L., Magrì, A., Maione, F., Russo, M., Crisafulli, G., Bartolini, A., Lerda, G., et al. (2017) · Nature · doi:10.1038/nature24673 · Cited by 627
Xia, T., Konno, H., Ahn, J., & Barber, G. N. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.029 · Cited by 589
Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
Daud, A. I., Loo, K., Pauli, M. L., Sanchez-Rodriguez, R., Sandoval, P. M., Taravati, K., Tsai, K., Nosrati, A., Nardo, L., Alvarado, M. D., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87324 · Cited by 525
TGFβ is a master regulator of radiation therapy-induced antitumor immunity
Vanpouille-Box, C., Diamond, J. M., Pilones, K. A., Zavadil, J., Babb, J. S., Formenti, S. C., Barcellos-Hoff, M. H., & Demaria, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3511 · Cited by 514
Host STING-dependent MDSC mobilization drives extrinsic radiation resistance
Liang, H., Deng, L., Hou, Y., Meng, X., Huang, X., Rao, E., Zheng, W., Mauceri, H., Mack, M., Xu, M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01566-5 · Cited by 488
The host STING pathway at the interface of cancer and immunity
Corrales, L., McWhirter, S. M., Dubensky, T. W., & Gajewski, T. F. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86892 · Cited by 487
Transforming Growth Factor-β and the Immune Response: Implications for Anticancer Therapy
Wrzesinski, S. H., Wan, Y. Y., & Flavell, R. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1157 · Cited by 452
Inflammation-driven carcinogenesis is mediated through STING
Ahn, J., Xia, T., Konno, H., Konno, K., Ruiz, P., & Barber, G. N. (2014) · Nature Communications · doi:10.1038/ncomms6166 · Cited by 447
Ku, G. Y., Yuan, J., Page, D. B., Schroeder, S. E. A., Panageas, K. S., Carvajal, R. D., Chapman, P. B., Schwartz, G. K., Allison, J. P., & Wolchok, J. D. (2010) · Cancer · doi:10.1002/cncr.24951 · Cited by 422
Recurrent Loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis
Xia, T., Konno, H., & Barber, G. N. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1404 · Cited by 383
Tang, C., Liao, Z., Gomez, D., Levy, L., Zhuang, Y., Gebremichael, R. A., Hong, D. S., Komaki, R., & Welsh, J. W. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.04.025 · Cited by 372
Current clinical trials testing the combination of immunotherapy with radiotherapy
Kang, J., Demaria, S., & Formenti, S. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0156-7 · Cited by 371
Liu, J., Liao, S., Diop-Frimpong, B., Chen, W., Goel, S., Naxerova, K., Ancukiewicz, M., Boucher, Y., Jain, R. K., & Xu, L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117610109 · Cited by 330
STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation
Lemos, H., Mohamed, E., Huang, L., Ou, R., Pacholczyk, G., Arbab, A. S., Munn, D., & Mellor, A. L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1456 · Cited by 325
Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy
Young, K. H., Baird, J. R., Savage, T., Cottam, B., Friedman, D., Bambina, S., Messenheimer, D. J., Fox, B., Newell, P., Bahjat, K. S., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157164 · Cited by 325
Oshima, Y., Tanimoto, T., Yuji, K., & Tojo, A. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4526 · Cited by 313
Diem, S., Kasenda, B., Spain, L., Martin-Liberal, J., Marconcini, R., Gore, M., & Larkin, J. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.467 · Cited by 308
Martin, A. M., Cagney, D. N., Catalano, P. J., Alexander, B. M., Redig, A. J., Schoenfeld, J. D., & Aizer, A. A. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3993 · Cited by 307
Klopp, A. H., Spaeth, E. L., Dembinski, J. L., Woodward, W. A., Munshi, A., Meyn, R. E., Cox, J. D., Andreeff, M., & Marini, F. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1406 · Cited by 304
The mechanism of action of radiosensitization of conventional chemotherapeutic agents
Lawrence, T. S., Blackstock, A. W., & McGinn, C. (2003) · Seminars in Radiation Oncology · doi:10.1053/srao.2003.50002 · Cited by 296
A review of human cell radiosensitivity in vitro
Deschavanne, P. J., & Fertil, B. (1996) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)02029-2 · Cited by 295
Radiation and immunotherapy: a synergistic combination
Kalbasi, A., June, C. H., Haas, N., & Vapiwala, N. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69219 · Cited by 284
The convergence of radiation and immunogenic cell death signaling pathways
Golden, E. B., Pellicciotta, I., Demaria, S., Barcellos-Hoff, M. H., & Formenti, S. C. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00088 · Cited by 282
Innate Immune Recognition of an AT-Rich Stem-Loop DNA Motif in the Plasmodium falciparum Genome
Sharma, S., DeOliveira, R. B., Kalantari, P., Parroche, P., Goutagny, N., Jiang, Z., Chan, J., Bartholomeu, D. C., Lauw, F., Hall, J. P., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.05.016 · Cited by 262
Baird, J. R., Friedman, D., Cottam, B., Dubensky, T. W., Kanne, D. B., Bambina, S., Bahjat, K., Crittenden, M. R., & Gough, M. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-3619 · Cited by 257
Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy
Davuluri, R., Jiang, W., Fang, P., Xu, C., Komaki, R., Gomez, D. R., Welsh, J., Cox, J. D., Crane, C. H., Hsu, C. C., et al. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.05.037 · Cited by 257
Self-citationRadiation abscopal antitumor effect is mediated through p53.
Camphausen, K. A., Moses, M. A., Ménard, C. M., Sproull, M. T., Beecken, W.-D. C., Folkman, J., & O’Reilly, M. S. (2003) · PubMed · Cited by 254
Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer
Shukuya, T., & Carbone, D. P. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.02.015 · Cited by 245
Perrin, P. J., Maldonado, J. H., Davis, T. A., June, C. H., & Racke, M. K. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.4.1333 · Cited by 226
Qian, J. M., Yu, J. B., Kluger, H. M., & Chiang, V. L. S. (2016) · Cancer · doi:10.1002/cncr.30138 · Cited by 212
Khagi, Y., Goodman, A. M., Daniels, G. A., Patel, S. P., Sacco, A. G., Randall, J. M., Bazhenova, L. A., & Kurzrock, R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1439 · Cited by 202
Frey, B., Rückert, M., Deloch, L., Rühle, P. F., Derer, A., Fietkau, R., & Gaipl, U. S. (2017) · Immunological Reviews · doi:10.1111/imr.12572 · Cited by 180
Immune Priming of the Tumor Microenvironment by Radiation
Jiang, W., Chan, C. K., Weissman, I. L., Kim, B. Y. S., & Hahn, S. M. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.09.007 · Cited by 178
Self-citationHryniewicz, A., Boasso, A., Edghill-Smith, Y., Vaccari, M., Fuchs, D., Venzon, D., Nacsa, J., Betts, M. R., Tsai, W.-P., Heraud, J.-M., et al. (2006) · Blood · doi:10.1182/blood-2006-04-010637 · Cited by 174
Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy
Yuan, H., Jiang, W., von Roemeling, C. A., Qie, Y., Liu, X., Chen, Y., Wang, Y., Wharen, R. E., Yun, K., Bu, G., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.69 · Cited by 172
Self-citationShiraishi, Y., Fang, P., Xu, C., Song, J., Krishnan, S., Koay, E. J., Mehran, R. J., Hofstetter, W. L., Blum-Murphy, M., Ajani, J. A., et al. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.11.028 · Cited by 163
Self-citationEpidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies
Milas, L., Fan, Z., Andratschke, N. H., & Ang, K. K. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.08.035 · Cited by 162
Vermeer, D. W., Spanos, W. C., Vermeer, P. D., Bruns, A. M., Lee, K. M., & Lee, J. H. (2013) · International Journal of Cancer · doi:10.1002/ijc.28015 · Cited by 109
Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy
Torphy, R. J., Schulick, R. D., & Zhu, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122642 · Cited by 101
Alotaibi, M. R., Sharma, K., Saleh, T., Povirk, L. F., Hendrickson, E. A., & Gewirtz, D. A. (2016) · Radiation Research · doi:10.1667/rr14202.1 · Cited by 91
Potential of radiosensitizing agents in cancer chemo-radiotherapy
Mishra, K. P., Girdhani, S., Bhosle, S., Thulsidas, S., & Kumar, A. (2005) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.19585 · Cited by 88
The dual adverse effects of TGF-β secretion on tumor progression
Trapani, J. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.018 · Cited by 80
Active Immunotherapy Induces Antibody Responses That Target Tumor Angiogenesis
Schoenfeld, J. D., Jinushi, M., Nakazaki, Y., Wiener, D. C., Park, J., Soiffer, R. J., Neuberg, D. S., Mihm, M. C., Hodi, F. S., & Dranoff, G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1852 · Cited by 78
Yoshimoto, Y., Oike, T., Okonogi, N., Suzuki, Y., Ando, K., Sato, H., Noda, S.-E., Isono, M., Mimura, K., Kono, K., et al. (2015) · Journal of Radiation Research · doi:10.1093/jrr/rrv007 · Cited by 72
Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy
Liikanen, I., Koski, A., Merisalo-Soikkeli, M., Hemminki, O., Oksanen, M., Kairemo, K., Joensuu, T. K., Kanerva, A., & Hemminki, A. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.989771 · Cited by 62
Integration of radiation and immunotherapy in breast cancer - Treatment implications
Ye, J. C., & Formenti, S. C. (2018) · The Breast · doi:10.1016/j.breast.2017.12.005 · Cited by 56
Shi, F., Wang, X., Teng, F., Kong, L., & Yu, J. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1276133 · Cited by 52
Possible Interaction of Anti–PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases
Alomari, A. K., Cohen, J. V., Vortmeyer, A. O., Chiang, A. C., Gettinger, S. N., Goldberg, S. B., Kluger, H. M., & Chiang, V. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0238 · Cited by 51
Defining Molecular Signature of Pro-Immunogenic Radiotherapy Targets in Human Prostate Cancer Cells
Aryankalayil, M. J., Makinde, A. Y., Gameiro, S. R., Hodge, J. W., Rivera-Solis, P. P., Palayoor, S. T., Ahmed, M. M., & Coleman, C. N. (2014) · Radiation Research · doi:10.1667/rr13731.1 · Cited by 50
Haymaker, C., Kim, D. W., Uemura, M. I., Vence, L. M., Phillip, A., McQuail, N., Brown, P. D., Fernandez, I., Hudgens, C. W., Creasy, C. A., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0223 · Cited by 49
Schoenhals, J. E., Seyedin, S. N., Tang, C. Z., Cortez, M. A., Niknam, S., Tsouko, E., Chang, J. Y., Hahn, S. M., & Welsh, J. W. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000181 · Cited by 47
Remón, J., Chaput, N., & Planchard, D. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000263 · Cited by 46
Nagasaka, M., Zaki, M., Kim, H., Raza, S. N., Yoo, G., Lin, H.-S., & Sukari, A. (2016) · Journal of Immunotherapy for Cancer · doi:10.1186/s40425-016-0187-0 · Cited by 43
Flynn, J. P., O’Hara, M. H., & Gandhi, S. J. (2007) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.03.07 · Cited by 43
Feng, F. Y.-C., Speers, C. W., Liu, M., Jackson, W., Moon, D. H., Rinkinen, J. R., Wilder-Romans, K., Jagsi, R., & Pierce, L. J. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3085-5 · Cited by 39
Kumar, S. S., Higgins, K. A., & McGarry, R. C. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00197 · Cited by 26
Efficacy and Toxic Effects of Cancer Immunotherapy Combinations—A Double-edged Sword
Tang, C. Z., Jiang, W., & Yap, T. A. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4606 · Cited by 20
Self-citationSon, C. H., Fleming, G. F., & Moroney, J. W. (2017) · Cancer Management and Research · doi:10.2147/cmar.s116683 · Cited by 16
Cited by
Treatment of muscle‐invasive and advanced bladder cancer in 2020
Patel, V. G., Oh, W. K., & Galsky, M. D. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21631 · Cited by 1,014
Fares, C. M., Van Allen, E. M., Drake, C. G., Allison, J. P., & Hu-Lieskovan, S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_240837 · Cited by 653
Tumor Microenvironment as A “Game Changer” in Cancer Radiotherapy
Jarosz-Biej, M., Smolarczyk, R., Cichoń, T., & Kułach, N. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133212 · Cited by 546
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
Butterfield, L. H., & Najjar, Y. G. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-023-00973-8 · Cited by 330
Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion
Jiang, N., Xie, B., Xiao, W., Fan, M., Xu, S., Duan, Y., Hamsafar, Y., Evans, A. C., Huang, J., Zhou, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29137-3 · Cited by 258
Metadata
- Authors
- Wang, Y., Deng, W., Li, N., Neri, S., Sharma, A., Jiang, W., & Lin, S. H.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2018-03-05
- Volume
- 9
- Pages
- 185-185
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2791567488
- Cited by
- 374
- References
- 103
- FWCI
- 16.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.